奥扎格雷钠对老年冠状动脉粥样硬化性心脏病患者血栓素B2和6-酮前列腺素F1α水平的影响及意义

摘要

Objective To observe the effects of sodium ozagrel on the levels of TXB2 and 6 - keto - PGF1α in the patients with coronary heart disease( CHD ) and to explore its application value in treating CHD. Methods Totally 120 cases of CHD diagnosed by coronary angiography were randomly divided into the conventional treatment group( n = 60 ) and the ozagrel treatment group( n = 60 ). Then the plasma levels of TXB2 and 6 - keto - PGF1α before and after treatment were measured and compared between the two groups. The coronary artery lesions were measured by the Gensini score system and its correlation with levels of TXB2 and 6-keto-PGF1α was analyzed. Results The level of TXB2 in the patients with CHD was significantly higher than that in the control group( P < 0.05), and the level of 6-keto-PGF1α was significantly lower than that in the control group ( P < 0. 05 ). The Gensini score showed the positive correlation with the level of TXB2( r = 0. 491, P < 0. 05 ) and the negative correlation with the level of 6-keto-PGF1α ( r = -0. 618, P < 0. 05 ). The levels of TXB2 after treatment in the two groups were decreased and the levels of 6-keto-PGFia were increased, showing statistical differences as compared with before treatment ( P < 0. 05 ). The level TXB2 after treatment in the ozagrel treatment group was significantly lower than that in the conventional treatment group( P < 0.05), while the level of 6-keto-PGF1α was higher than that in the conventional treatment group( P < 0. 05 ). Conclusion Sodium ozagrel can significantly decrease the level of TXB2 and increase the level of 6 - keto - PGF1α ,improve the TXB2/6 - keto - PGF1α balance and delay vascular pathological changes.%目的 观察奥扎格雷钠对冠状动脉粥样硬化性心脏病患者血中血栓素B2(TXB2)和6-酮前列腺素F1α(6-keto-PGF1α)的影响,探讨其在冠心病治疗中的应用价值.方法 将冠状动脉造影确诊的患者120例随机分为常规治疗组60例和奥扎格雷钠治疗组60例,分别测定两组患者治疗前后血浆TXB2和6-keto-PGF1α水平并进行对比分析.采用Gensini评分系统测定冠状动脉病变程度,并与血浆TXB2和6-keto-PGF1α水平进行相关性分析.结果 冠状动脉粥样硬化性心脏病患者TXB2明显高于对照组(P＜0.05),6-keto-PGF1α明显低于对照组(P＜0.05);冠状动脉粥样硬化性心脏病患者血浆TXB2水平与Gensini评分呈正相关(r=0.491,P＜0.05),6-keto-PGF1α与Gensini积分呈负相关(r=-0.618,P＜0.05);治疗后两组患者TXB2水平均降低,6-keto-PGF1α均增高,与治疗前比较差异有统计学意义(P＜0.05);治疗后奥扎格雷钠TXB2水平明显低于常规治疗组(P＜0.05),6-keto-PGF1α水平明显高于常规治疗组(P＜0.05).结论 奥扎格雷钠可显著降低冠状动脉粥样硬化性心脏病患者TXB2水平,升高6-keto-PGF1α水平,改善TXB2/6-keto-PGF1α平衡,延缓血管病变.